Which research peptide vendors shut down in 2025 and 2026?
The research peptide market went through a wave of vendor closures between mid-2025 and mid-2026, driven by the most aggressive federal enforcement the sector has faced. The single most significant closure was Peptide Sciences, the largest vendor by web traffic, which voluntarily ceased operations in early March 2026. Beyond that confirmed shutdown, industry vendor-status trackers have documented a broader cluster of suppliers going offline across the same window.
The most widely reported events are the voluntary shutdown of Peptide Sciences in March 2026 and the federal warehouse raid on Amino Asylum in June 2025. Both are covered in detail in our analysis of why Peptide Sciences shut down. Vendor trackers covering the space have counted at least eight notable suppliers that went dark during 2025 and 2026, though the level of public confirmation varies from vendor to vendor. Some issued shutdown notices on their own domains; others simply stopped fulfilling orders without any statement.
For researchers, the practical takeaway is not the exact count. It is that single-supplier dependence became a real continuity risk. A vendor generating millions in monthly revenue closed overnight with no warning, and several smaller suppliers followed. The reliable way to know a specific vendor's current status is to check it directly, which we cover below, rather than relying on rumor or social media speculation.
Why are research peptide companies shutting down?
The closures did not happen in isolation. They followed a sustained escalation of federal enforcement against the research peptide and compounding pharmacy industries through 2025 and into 2026. Several converging factors made continued operation progressively riskier.
FDA enforcement escalation. Beginning in September 2025, the FDA issued more than 50 warning letters to peptide vendors, compounding pharmacies, and related businesses, citing violations from unapproved drug distribution to misbranding and manufacturing deficiencies. The pace was unprecedented for the sector, and each letter carried the implicit threat of injunctions, seizures, and criminal referral.
The Amino Asylum warehouse raid. In June 2025, federal agents raided the warehouse operations of Amino Asylum, a prominent vendor. The raid marked a shift from warning letters to direct physical enforcement and signaled that the FDA was willing to deploy its most aggressive tools. Industry observers widely view it as a turning point that prompted several vendors to reassess their risk exposure.
Resolution of the semaglutide shortage. In February 2025, the FDA formally resolved the semaglutide drug shortage. That resolution removed the loophole that had allowed compounding pharmacies, and by extension some research vendors, to produce GLP-1 analogs under Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act. Because GLP-1 related compounds generated enormous revenue, losing that category materially changed the economics for many suppliers.
The SAFE Drugs Act. Introduced in early 2026, the Strengthening and Advancing Federal Enforcement of Drugs Act proposed expanded FDA authority to pursue entities distributing unapproved peptide products. The legislation signaled bipartisan support for tighter regulation even before passage.
Third-party testing failures. Independent analyses published by third-party testing services exposed quality concerns across multiple vendors, including documented counterfeit retatrutide and substandard CJC-1295 batches. When independent testing shows products do not meet advertised specifications, it compounds regulatory risk by providing evidence of potential misbranding.
Taken together, these pressures created what many analysts describe as an untenable operating environment for vendors without robust compliance and quality systems.
Did Pura Peptides shut down?
As of mid-2026, there is no verified public record that Pura Peptides has ceased operations. The name appears in community discussion and forum speculation about which vendors might face regulatory pressure next, but speculation is not a confirmed closure. Researchers searching for the status of any specific vendor should treat unconfirmed forum predictions as exactly that.
This distinction matters. The 2025-2026 enforcement wave has generated a large volume of rumor, and vendor status can change quickly. The responsible approach is to verify a supplier's current operating status directly before relying on or ruling out any vendor. The same verification steps apply whether a vendor is rumored to be closing or simply new to you. The next section covers how to check.
How can researchers verify whether a peptide vendor is still operating?
Rather than depending on social media or aggregator lists that can lag reality, researchers can confirm a vendor's status with a few direct checks. These steps take minutes and are more reliable than secondhand reports.
Check the vendor's own domain. A shutdown vendor typically replaces its storefront with a static notice or lets the site lapse. An operating vendor maintains a live catalog with current pricing and stock status. A site that loads but cannot process an order is a warning sign.
Confirm order fulfillment and support are active. Look for responsive customer service channels and recent, verifiable fulfillment activity. Vendors winding down often go dark on support before the website disappears.
Look for current batch documentation. An operating, quality-focused vendor publishes recent batch-specific Certificates of Analysis. Stale or missing documentation can indicate a supplier that has stopped investing in quality operations.
Cross-reference independent sources. Industry trackers and testing services provide useful signals, but treat any single list as one data point, not confirmation. Corroborate across multiple sources before drawing a conclusion about a specific vendor.
What should researchers look for when choosing a new supplier in 2026?
In the post-shutdown landscape, researchers qualifying a replacement supplier should apply rigorous criteria before placing orders. The quality failures documented across the industry make due diligence more important than ever. The following standards represent the minimum threshold for a credible research peptide vendor in the current environment.
Batch-specific third-party Certificate of Analysis. A legitimate COA accompanies every batch and is not available only on request. It should be batch-specific, with batch numbers, testing dates, and testing laboratory identification. Generic COAs reused across batches are a red flag. For a full guide, see how to read a Certificate of Analysis.
HPLC verification and mass spectrometry. High-Performance Liquid Chromatography is the standard for purity quantification, and mass spectrometry confirms identity. Suppliers should provide both for every compound, including the actual chromatogram images rather than only a numerical percentage. Our article on peptide purity covers why these methods matter.
Endotoxin testing. Bacterial endotoxin is a critical quality parameter for compounds used in cell culture and in vitro assays. Limulus Amebocyte Lysate testing or recombinant Factor C assays detect contamination. Suppliers who skip this step are cutting corners on fundamental quality assurance.
Cold-chain shipping as standard. Peptides degrade through oxidation, aggregation, and deamidation when exposed to heat in transit. A compound that leaves at 99% purity can arrive degraded without thermal protection. Cold-chain handling should be standard, not a paid add-on. See our guide on cold-chain shipping.
Transparent purity data. Research-grade compounds should meet a minimum purity threshold of 98%, with premium applications requiring 99% or higher. Be wary of vendors who advertise a purity number but cannot produce the underlying chromatographic evidence.
US-based operations. Domestic operations provide accountability, faster shipping, and clearer regulatory jurisdiction, which simplifies dispute resolution and quality complaints.
These criteria are not aspirational. They are the baseline for responsible research compound sourcing in an era where the consequences of quality failures extend beyond wasted experiments.
How is Amino Foundry positioned in this market?
Amino Foundry was built to meet the quality and transparency standards the research community increasingly demands. Rather than positioning as a replacement for any specific closed vendor, it operates on a quality framework designed to address the documented gaps that defined the broader market. All compounds are intended solely for research purposes and are not for human use.
Amino Foundry maintains a catalog of research-grade compounds, each held to a minimum purity standard of 99% or higher as verified by independent third-party analytical testing. Every order ships with a batch-specific Certificate of Analysis documenting HPLC purity quantification and mass spectrometry identity confirmation, included as standard rather than on request. Endotoxin testing is performed using validated detection methods, and all shipments are cold-chain packaged as standard, not as an upgrade. Operations are based entirely in the United States.
Researchers who previously relied on a single supplier can review the full catalog, pricing, and category organization by browsing all compounds. For researchers specifically evaluating alternatives to a closed vendor, our guide on choosing a Peptide Sciences alternative walks through the comparison in detail.
The broader lesson from the 2025-2026 shutdowns is that research supply chains built around a single source carry inherent risk. Diversifying suppliers, maintaining independent records of COAs and batch data from every order, and verifying vendor status directly are the most effective ways to keep research continuity intact through a period of rapid regulatory change.
All compounds referenced in this article are research chemicals intended for laboratory and scientific research purposes only. Amino Foundry does not sell products intended for human consumption. Researchers are responsible for ensuring compliance with all applicable local, state, and federal regulations governing the purchase and use of research materials.